The global intestinal fistula treatment market is expected to be valued at USD 26.64 Billion in 2023. With the continuous improvements in drugs and biotechnology, the overall demand for Intestinal Fistula Treatment is projected to grow at a CAGR of 5.8% between 2023 and 2033, totaling around USD 46.82 Billion by 2033.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value for Intestinal Fistula Treatment in 2023 | USD 26.64 Billion |
| Projected Market Value for Intestinal Fistula Treatment in 2033 | USD 46.82 Billion |
| Global Growth Rate (2023 to 2033) | CAGR of 5.8% |
According to the analysis of Future Market Insights, factors such as a rise in the inflammatory bowel disease (IBD) patient pool, increase in the prevalence of Crohn’s disease, approval of new biologic drugs, novel drugs pipeline, and increase in demand for application of intestinal fistula treatment in developing countries are expected to augment the growth of the intestinal fistula treatment market.
Reimbursement plans introduced by the leading players to cushion healthcare expenditure will lead to positive sentiment among patients toward effective treatment. Growth in investments in the treatment of intestinal fistula is also anticipated to help achieve high ROI, as physicians tend to prescribe these drugs for the treatment of moderate to severe intestinal fistula. In addition, the development of anti-adhesion molecules is likely to propel the adoption of integrin antagonists.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global demand for intestinal fistula treatment is projected to increase at a CAGR of 5.8% during the forecast period between 2023 and 2033, reaching a total of USD 46.82 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 3.2%. According to Future Market Insights, a market research and competitive intelligence provider, the Intestinal Fistula Treatment market was valued at USD 25.18 Billion in 2022.
The global rise in the prevalence of intestinal fistula is driving the growth of the intestinal fistula treatment market. The major cause of the disease includes inflammatory bowel diseases, which result in long-term chronic inflammation of the gastrointestinal (GI) tract without any known cause. Factors such as innovations in product development, approval of drugs, and rising inclination toward the use of biologic and biosimilar drugs are expected to boost the revenue share of intestinal fistula treatment during the forecast period. Growth in sales of intestinal fistula drugs through online, retail, and hospital pharmacies is helping companies generate more revenues. For instance, in December 2019, the FDA approved two biosimilars - adalimumab and infliximab - for the treatment of Ulcerative Colitis.
Biopharmaceutical companies have made significant investments in Research and Development activities. Large numbers of pipeline products are in different stages of clinical approvals, which are likely to commercialize over the analysis period. According to a report, around 2.5 million people in the USA suffered from inflammatory bowel disease in 2020. The prevalence of IBD among the USA population is expected to rise to around 3.5 million by 2030. Similarly, data suggest that the incidence and prevalence of inflammatory bowel diseases [IBD] are still increasing in Europe; around 0.2% of the population of Europe suffered from IBD in 2020. This in turn is anticipated to accelerate market growth in the forthcoming years.
Increasing focus on Research and Development for the Treatment of Intestinal Fistula to Fuel the Market Growth
Technological development, such as the use of single-cell RNA sequencing, is helping healthcare professionals in the treatment of intestinal fistula treatment. High-dimensional technologies such as single-cell RNA sequencing and mass cytometry have been performed on the intestinal specimens collected from patients suffering from Crohn’s disease or ulcerative colitis. Several benefits of the single-cell RNA sequencing analysis used to understand the molecular basis of the disease include the development of novel therapeutic approaches, optimizing the individual medicines, and preventing the disease.
For instance, in August 2020, The University of California and VA San Diego Healthcare System (VASDHS) used transcriptomic and antigen receptor sequencing strategies to characterize tissue and immune cell features in individuals with or without ulcerative colitis. These advancements in technology provide an unusual view of immune cell networks in health and disease. These factors are expected to escalate the growth of the intestinal fistula treatment market during the forecast period.
Rise in Awareness Regarding Intestinal Fistula to Accelerate the Market Growth
There are numerous factors that are responsible for the increasing prevalence of intestinal fistula treatment market, which are genetic predisposition, environmental triggers, and immune system disturbance, which all are results of Crohn’s Disease. The majority of the patients suffering from ulcerative colitis or Crohn’s disease have a family history of the disorder.
For instance, according to a research study conducted by Hopkins Medicine, about 10 to 15% of the patients suffering from Crohn’s disease have a family history of the disorder. Approximately 5 to 7% of the patients suffering from ulcerative colitis have a family history of the disorder.
Various government organizations are creating awareness about intestinal fistula by educating people about the symptoms, diagnosis, and treatments available for the condition. Hence, the rising awareness about the treatment options available and the increasing rate of disease diagnosis in developing countries are projected to support the market growth. Thus, the aforementioned factors are leading to increasing demand for drugs over the analysis period.
Principal Consultant
High Cost of Intestinal Fistula Drugs to Limit the Market Growth
The high treatment cost of the intestinal fistula, including the drug cost and other costs, reducing the number of patients undergoing treatment are expected to hinder the adoption of intestinal fistula treatment in patients. Additionally, the adoption of biologics is increasing to treat the disease, but the high costs associated with biologics treatment are limiting the market growth.
For instance, according to the National Center for Biotechnology Information (NCBI), the average annual cost of Adalimumab per person is about USD 12,343 in the United Kingdom In emerging countries, such as India, China, and Russia, there is a lack of reimbursement for intestinal fistula treatment, limiting the adoption of these drugs in the region. Hence, the high cost of medications for treating the disease and the lack of reimbursement policies in developing countries are anticipated to impede market growth in the near future.
Increase in Prevalence of Ulcerative Colitis in the Region to Fuel the Market Growth
The intestinal fistula treatment market in North America is expected to accumulate the highest market share of 45% in 2023. Factors such as the high prevalence and increase in the incidence of ulcerative colitis and Crohn’s disease in the USA and Canada, well-established healthcare infrastructure, and high risk of lifestyle-related factors are expected to augment the regional market growth during the forecast period.
Moreover, the strong product pipeline of key players is another major factor that is anticipated to fuel the market growth in the region. For instance, according to the National Center for Biotechnology Information (NCBI), the prevalence of inflammatory bowel disease in Canada will be over 0.75% in 2021. The region is expected to hold the highest CAGR of 5.7% during the forecast period.
Rising Awareness Regarding Available Treatment Options in the Region to Fuel the Market Growth
The intestinal fistula treatment market in the Asia Pacific is expected to accumulate the highest market share of 44% in 2023. The intestinal treatment market in China is anticipated to grow at a significant share over the analysis period. attributed to the factors such as an increase in the intestinal fistula patient pool and a rise in the focus of manufacturers on the development of novel therapeutics.
Additionally, factors including increasing awareness about available treatment options for the disease in the region and increasing approvals for the drugs for the treatment of the disease are also expected to fuel the regional market growth. For instance, in December 2021, Eisai Co., Ltd. and Gilead Sciences, Inc. agreed to the commercialization and distribution of filgotinib, an oral, JAK1 preferential inhibitor for indications of ulcerative colitis and Crohn's disease in Asia (South Korea, Taiwan, Hong Kong, and Singapore).
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Proton-Pump Inhibitors Segment to beat Competition in Untiring Market
On the basis of drug class, proton-pump inhibitors are likely to account for 45% of all drug sales. The segment is expected to augment at a CAGR of 5.7% over the analysis period. Growth is attributed to the factors such as the fact that the PPIs inhibit acid secretion, whether promoted by histamine, acetylcholine, or gastrin.
Moreover, PPIs work by irreversibly blocking the H+/K+ ATPase enzyme or the gastric proton pump, which is found within the parietal cells of the stomach and is the final step of acid production. All these factors are expected to stimulate the segment’s growth during the forecast period.
Hospital Pharmacies account for the bulk of all Intestinal Fistula Treatment Medication Sales
Based on distribution channels, hospital pharmacies are expected to account for 46% of intestinal fistula treatment medication sales in 2023 and are expected to grow at a 5.6% CAGR until 2033. Growth is attributed to the fact that most of the major intestinal fistula treatment drugs and products are prescription products, which are available in hospital pharmacies.
Furthermore, the segment dominated the market with a significant share, attributed to reimbursement policies in developing countries, which cover the high cost of these drugs. For instance, according to Baylor Scott & White, in the USA, approximately 45% of the costs are covered by the pharmacy, including injectable drugs and others.
Intestinal Fistula Treatment Market startup players are adopting various marketing strategies such as new product launches, geographical expansion, mergers and acquisitions, partnerships, and collaboration to identify the interest of potential patients and create a larger customer base. For instance,
In June 2021, Gusto Global, a microbiome discovery platform company focused on restoring a healthy microbiome, developed novel consortia of bacteria for treating Crohn’s disease and ulcerative colitis in patients.
In April 2019, Signum Surgical, an Ireland-based startup landed more than USD3 million in grants to help fund its efforts to gain U.S. and European regulatory clearance for a device intended to treat a condition that can cause fecal incontinence. The BioHealx technology is designed to treat anal fistula.
In May 2018, Oshi Health, a digital startup focused on digestive health, launched a mobile app specifically designed to help inflammatory bowel disease patients understand and manage their condition. The app has an all-in-one mobile platform with three primary aims: condition and lifestyle tracking, patient education, and active IBD management.
Prominent players in the intestinal fistula treatment market are:
Recent Developments:
In December 2022, Moderna, Inc., and Merck announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA®, Merck’s anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of recurrence-free survival (RFS) versus KEYTRUDA alone for the adjuvant treatment of patients with stage III/IV melanoma following complete resection. Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA reduced the risk of recurrence or death by 44% (HR=0.56 [95% CI, 0.31-1.08]; one-sided p value=0.0266) compared with KEYTRUDA alone.
In September 2022, Bristol Myers Squibb announced that the Phase 3 CheckMate -76K trial evaluating Opdivo (nivolumab) as a single agent in the adjuvant setting in patients with completely resected stage IIB/C melanoma met its primary endpoint and demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival (RFS) versus placebo at a pre-specified interim analysis. No new safety signals were observed at the time of the analysis.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 5.8% from 2023 to 2033 |
| Market Value in 2023 | USD 26.64 Billion |
| Market Value in 2033 | USD 46.82 Billion |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Drug Class, Route of Administration, Distribution Channel, Region |
| Regions Covered | North America; Asia Pacific; Europe; Latin America; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, China, Japan, South Korea, Indonesia, Thailand, Singapore, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Livealth BioPharma; Boehringer Ingelheim International GmbH; Pfizer Inc.; Apsolabs; AstraZeneca; Pipelinepharma; Astellas Pharma Inc.; Caspian Tamin Pharmaceutical Company; Eli Lilly; GlaxoSmithKline; Bristol-Myers Squibb; Merck & Co. KGaA; Moderna Inc. |
| Customization | Available upon Request |
Asia Pacific is expected to accumulate a market share of 44% in 2023.
From 2018 to 2022, the market registered a CAGR of 5.8%.
The market is likely to register a 5.8% CAGR Until 2033.
The industry is expected to reach USD 46.82 billion in 2033.
North America is expected to accumulate a high market share of 45% in 2023.
1. Executive Summary | Intestinal Fistula Treatment Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Anticholinergic 5.2. Proton-pump Inhibitors 5.3. H2 Blockers 5.4. Antidiarrheals 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 6.1. Oral 6.2. Parenteral 6.3. Rectal 6.4. Transdermal 6.5. Intravenous 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Hospital Pharmacies 7.2. Clinical Pharmacies 7.3. Drug Stores 7.4. Online Pharmacies 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. Asia Pacific 8.5. Middle East and Africa (MEA) 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Key Countries Market Analysis 15. Market Structure Analysis 16. Competition Analysis 16.1. Livealth BioPharma 16.2. Boehringer Ingelheim International GmbH 16.3. Pfizer 16.4. Apsolabs 16.5. AstraZeneca 16.6. Pipelinepharma 16.7. Astellas Pharma Inc 16.8. Caspian Tamin Pharmaceutical Company 16.9. Eli Lilly 16.10. GlaxoSmithKline 17. Assumptions & Acronyms Used 18. Research Methodology
Explore Healthcare Insights
View Reports
Intestinal Fistula Treatment Market
